CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
High ImpactOriginal article

Mureva Announces FDA De Novo Authorization and Peer-Reviewed Publication of Pivotal Mureva OM Trial

RegulatoryapprovedMureva OMPositive
AI Analysis

Summary

Mureva Phototherapy Inc. received FDA De Novo authorization for Mureva OM, a phototherapy device for treating severe oral mucositis, supported by a randomized, sham-controlled pivotal trial published in a peer-reviewed journal.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

FDA granted De Novo authorization for Mureva OM

Importance:8/10
Sentiment:
0.90
FDA approvalDe Novo authorizationoral mucositisphototherapyrandomized controlled trialpeer-reviewed publication

Read the original article

Published by PR Newswire Clinical Trials on September 10, 2026 1:00 PM

Read Original